Trends of Liver Stiffness in Inflammatory Bowel Disease with Chronic Hepatitis C

Concomitant inflammatory bowel disease (IBD) and hepatitis C virus (HCV) infection is a relevant comorbidity since IBD itself exposes to a high risk of liver damage. We aimed to evaluate liver stiffness (LS) in IBD-HCV after antiviral treatment. We enrolled IBD patients with HCV. All patients at baseline underwent LS measurement by elastography. Patients who were eligible for antiviral therapy received direct antiviral agents (DAAs) and sustained viral response was evaluated at the 12th week. A control group was selected within IBD patients without HCV. One year later, all IBD-HCV patients and controls repeated LS measurement. Twenty-four IBD-HCV patients and 24 IBD controls entered the study. Only twelve out of 24 received DAAs and all achieved sustained viral response (SVR). All IBD subjects were in remission at enrollment and maintained remission for one year. After one year, IBD patients who eradicated HCV passed from a liver stiffness of 8.5 &plusmn
6.2 kPa to 7.1 &plusmn
3.9, p = 0.13. IBD patients who did not eradicate HCV worsened liver stiffness: from 7.6 &plusmn
4.4 to 8.6 &plusmn
4.6, p = 0.01. In the IBD control group, stiffness decreased from 7.8 &plusmn
4.4 to 6.0 &plusmn
3.1, p &lt
0.001. In conclusion, HCV eradication is able to stop the evolution of liver fibrosis in IBD, while failure to treat may lead to its progression. A stable IBD remission may improve LS even in non-infected subjects.